Aarti Drugs (BOM:524348) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524348 Aarti Drugs Ltd BOM:524348
69 GF Score
Price ₹418.70
GF Value ₹511.03
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Aarti Drugs Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

BOM:524348
69GF Score
Aarti Drugs Ltd BOM:524348
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aarti Drugs (BOM:524348) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued. The current stock price of ₹418.70 is trading 18.1% below its estimated GF Value™ of ₹511.03. GuruFocus considers Aarti Drugs to be Modestly Undervalued.

Key valuation signals for BOM:524348:

  • Dividends Received:
  • GF Value™: ₹511.03 vs. price of ₹418.70 (18.1% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the BOM:524348 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aarti Drugs Business Description

Other Exchanges AARTIDRUGS:India
Address Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
69GF Score

Get the complete analysis for BOM:524348

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹418.70
Price
₹511.03
GF Value